Pediatrix (MD) director awarded 7,196 restricted shares in annual equity grant

Rhea-AI Filing Summary

Newman Kurt Douglas reported acquisition or exercise transactions in this Form 4 filing.

Pediatrix Medical Group director Kurt Douglas Newman received a grant of 7,196 shares of restricted common stock as an annual equity award. The award was granted at no cash cost to him under the company’s Amended and Restated 2008 Incentive Compensation Plan and will vest on May 7, 2027. After this grant, he directly holds 16,933 Pediatrix common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Newman Kurt Douglas

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,196	$0.00	--

Holdings After Transaction: Common Stock — 16,933 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Restricted stock grant: 7,196 shares Grant price: $0.00 per share Shares after transaction: 16,933 shares +1 more

4 metrics

Restricted stock grant 7,196 shares Restricted common stock awarded on May 7, 2026

Grant price $0.00 per share Equity compensation, no cash paid by director

Shares after transaction 16,933 shares Director’s direct holdings following the grant

Vesting date May 7, 2027 Vest date for 7,196 restricted shares

Key Terms

Restricted shares, Amended and Restated 2008 Incentive Compensation Plan, annual equity award, Grant, award, or other acquisition

4 terms

Restricted shares financial

"Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

Amended and Restated 2008 Incentive Compensation Plan financial

"Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan"

annual equity award financial

"in connection with annual equity award. Shares will vest on May 7, 2027."

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Newman Kurt Douglas

(Last) (First) (Middle)

1301 CONCORD TERRACE

(Street)

SUNRISE FLORIDA 33323

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pediatrix Medical Group, Inc. [ MD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/07/2026		A(1)		7,196	A	$0	16,933	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 7, 2027.

	Mary Ann E. Moore, Attorney-in-Fact	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Pediatrix Medical Group (MD) report for Kurt Douglas Newman?

Pediatrix Medical Group reported that director Kurt Douglas Newman received a grant of 7,196 shares of restricted common stock as an annual equity award, increasing his direct holdings to 16,933 shares following the transaction.

Was the Pediatrix Medical Group (MD) stock grant to Kurt Douglas Newman a purchase or a compensation award?

The transaction was a compensation-related award, not an open-market purchase. Newman received 7,196 restricted shares at no cash cost as an annual equity grant under Pediatrix’s Amended and Restated 2008 Incentive Compensation Plan.

When do Kurt Douglas Newman’s restricted Pediatrix (MD) shares vest?

The 7,196 restricted shares granted to director Kurt Douglas Newman will vest on May 7, 2027. Until vesting, the shares remain subject to restrictions as part of his equity-based compensation from Pediatrix Medical Group.

How many Pediatrix (MD) shares does Kurt Douglas Newman hold after this Form 4 transaction?

Following the restricted stock grant, Kurt Douglas Newman directly holds 16,933 shares of Pediatrix Medical Group common stock. This total includes the newly awarded 7,196 restricted shares reported in the Form 4 filing.

What plan governed the restricted stock grant to Pediatrix (MD) director Kurt Douglas Newman?

The restricted shares were granted under Pediatrix Medical Group’s Amended and Restated 2008 Incentive Compensation Plan. The Form 4 notes the award was made in connection with the company’s annual equity award program for eligible participants.